Virologica Sinica

, Volume 28, Issue 1, pp 49–52 | Cite as

A case of hepatitis B reactivation in an anti-HBs positive, anti-HBc positive non-Hodgkin’s lymphoma patient



Lymphoma Patient Virus Reactivation Escape Mutant Virus Escape Mutant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexopoulou A, Dourakis S P, Pandelidaki H, Archimandritis A J and Karayiannis P. 2006. Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol, 78: 1043–1046.PubMedCrossRefGoogle Scholar
  2. Awerkiew S, Daumer M, Reiser M, Wend U C, Pfister H, Kaiser R, Willems W R and Gerlich W H. 2007. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol, 38: 83–86.PubMedCrossRefGoogle Scholar
  3. Carman W F, Korula J, Wallace L, MacPhee R, Mimms L and Decker R. 1995. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet, 345: 1406–1407.PubMedCrossRefGoogle Scholar
  4. Dahlen D D, Broudy V C and Drachman J G. 2003. Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs. Blood, 102: 102–108.PubMedCrossRefGoogle Scholar
  5. Ferreira R, Carvalheiro J, Torres J, Fernandes A, Giestas S, Mendes S, Agostinho C and Campos M J. 2012. Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: A case report and literature review. Saudi J Gastroenterol, 18: 277–281.PubMedCrossRefGoogle Scholar
  6. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N and Sueoka E. 2009. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol, 20: 2013–2017.PubMedCrossRefGoogle Scholar
  7. Iannitto E, Minardi V, Calvaruso G, Mule A, Ammatuna E, Di Trapani R, Ferraro D, Abbadessa V, Craxi A and Di Stefano R. 2005. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol, 74: 254–258.PubMedCrossRefGoogle Scholar
  8. Lee I C, Huang Y H, Chu C J, Lee P C, Lin H C and Lee S D. 2010. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc, 73: 156–160.PubMedCrossRefGoogle Scholar
  9. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M and Takeuchi M. 2010. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer, 116: 4769–4776.PubMedCrossRefGoogle Scholar
  10. Mele A, Tancredi F, Romano L, Giuseppone A, Colucci M, Sangiuolo A, Lecce R, Adamo B, Tosti M E, Taliani G and Zanetti A R. 2001. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis, 184: 905–908.PubMedCrossRefGoogle Scholar
  11. Moerman B, Moons V, Sommer H, Schmitt Y and Stetter M. 2004. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab, 50: 159–162.PubMedGoogle Scholar
  12. Nainan O V, Khristova M L, Byun K, Xia G, Taylor P E, Stevens C E and Margolis H S. 2002. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol, 68: 319–327.PubMedCrossRefGoogle Scholar
  13. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M and Asaka M. 2005. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation, 79: 616–619.PubMedCrossRefGoogle Scholar
  14. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde K H, Neuhaus P and Gerken G. 1998. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology, 27: 254–263.PubMedCrossRefGoogle Scholar
  15. Sarrecchia C, Cappelli A and Aiello P. 2005. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother, 11: 189–191.PubMedCrossRefGoogle Scholar
  16. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, Matsuura B, Kajiwara T, Masumoto T, Horiike N and Onji M. 2006. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med, 45: 721–724.PubMedCrossRefGoogle Scholar
  17. Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, Kanamori H, Tanaka J, Asaka M, Imamura M and Masauzi N. 2004. Hepatitis B virus reactivation in a case of non-Hodgkin’s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma, 45: 627–629.PubMedCrossRefGoogle Scholar
  18. Westhoff T H, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer J H, Zidek W, Gerlich W H and Thiel E. 2003. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood, 102: 1930.PubMedCrossRefGoogle Scholar
  19. Wu C, Shi H, Wang Y, Lu M, Xu Y and Chen X. 2012. A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy. Virol Sin, 27: 368–371.PubMedCrossRefGoogle Scholar
  20. Yamagata M, Murohisa T, Tsuchida K, Okamoto Y, Tsunoda S, Nakamura M, Kusano K, Majima Y, Kuniyoshi T, Iijima M, Sugaya H and Hiraishi H. 2007. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma, 48: 431–433.PubMedCrossRefGoogle Scholar
  21. Yeo W, Chan T C, Leung N W, Lam W Y, Mo F K, Chu M T, Chan H L, Hui E P, Lei K I, Mok T S and Chan P K. 2009. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol, 27: 605–611.PubMedCrossRefGoogle Scholar
  22. Zhang J M, Xu Y, Wang X Y, Yin Y K, Wu X H, Weng X H and Lu M. 2007. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis, 44: 1161–1169.PubMedCrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.State Key Lab of Virology, Wuhan Institute of VirologyChinese Academy of SciencesWuhanChina
  2. 2.Department of Microbiology, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  3. 3.Institute of VirologyUniversity Hospital of EssenEssenGermany

Personalised recommendations